PD-1/L1

Delve into the world of PD-1/L1 in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on PD-1/L1 to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager
CompanyDeals

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager

Zymeworks Inc. (NASDAQ: ZYME) announced that it has entered into an exclusive global license and collaboration agreement with Roche for the research, development and commercialization of ZW209, a novel trispecific…

Bio‑Thera's BAT2306 Becomes World's First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis

Bio‑Thera’s BAT2306 Becomes World’s First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis

Eisai Issues First China Prescription for Leqembi (lecanemab) Subcutaneous Autoinjector at Ruijin Hainan Hospital – Home‑Friendly Dosing Marks New Era in Alzheimer's Treatment Access

Eisai Issues First China Prescription for Leqembi (lecanemab) Subcutaneous Autoinjector at Ruijin Hainan Hospital – Home‑Friendly Dosing Marks New Era in Alzheimer’s Treatment Access

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Hanx Biopharmaceuticals Receives NMPA Approval for HX009 Combination Therapy Phase II Trial

CompanyDrug

Innovent Biologics’ IBI363 Earns FDA Fast-Track Designation for Advanced Melanoma Treatment

CompanyDrug

Henlius Biotech’s HLX17 Biosimilar to MSD’s Keytruda Wins NMPA Clinical Trial Approval

CompanyDrug

Zuellig Pharma Partners with Regeneron for Libtayo Launch in South Korea and Taiwan

CompanyDrug

Sino Biopharmaceutical’s Anlotinib-Penpulimab Combo Meets Milestone in Phase III HCC Study

CompanyDrug

Mabwell Bioscience Initiates Phase III Trial for 9MW2821 Combo in Urothelial Carcinoma Following NMPA Clearance

CompanyDeals

ImmuneOnco Receives USD 10 Million Upfront Payment from Instil Bio Subsidiary for Licensing Deal

Drug

Akeso Biopharma’s Ivonescimab Earns Category 1 Recommendation in China’s 2024 Lung Cancer Clinical Guideline

Show More